BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27466504)

  • 21. Activated leukocyte cell adhesion molecule (ALCAM/CD166) expression in head and neck squamous cell carcinoma (HNSSC).
    Clauditz TS; von Rheinbaben K; Lebok P; Minner S; Tachezy M; Borgmann K; Knecht R; Sauter G; Wilczak W; Blessmann M; Münscher A
    Pathol Res Pract; 2014 Oct; 210(10):649-55. PubMed ID: 25028217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic evaluation for the potential translation of CD166-related expression as a cancer biomarker.
    Xiao M; Wang X; Yan M; Chen W
    Expert Rev Mol Diagn; 2016 Sep; 16(9):925-32. PubMed ID: 27398729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated leukocyte cell adhesion molecule (CD166): an "inert" cancer stem cell marker for non-small cell lung cancer?
    Tachezy M; Zander H; Wolters-Eisfeld G; Müller J; Wicklein D; Gebauer F; Izbicki JR; Bockhorn M
    Stem Cells; 2014 Jun; 32(6):1429-36. PubMed ID: 24501004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion.
    Jezierska A; Olszewski WP; Pietruszkiewicz J; Olszewski W; Matysiak W; Motyl T
    Med Sci Monit; 2006 Jul; 12(7):BR245-56. PubMed ID: 16810131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significant co-expression of putative cancer stem cell markers, EpCAM and CD166, correlates with tumor stage and invasive behavior in colorectal cancer.
    Kalantari E; Taheri T; Fata S; Abolhasani M; Mehrazma M; Madjd Z; Asgari M
    World J Surg Oncol; 2022 Jan; 20(1):15. PubMed ID: 35016698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALCAM is indirectly modulated by miR-125b in MCF7 cells.
    Akman HB; Selcuklu SD; Donoghue MT; Akhavantabasi S; Sapmaz A; Spillane C; Yakicier MC; Erson-Bensan AE
    Tumour Biol; 2015 May; 36(5):3511-20. PubMed ID: 25539763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis indicating that high ALCAM expression predicts poor prognosis in colorectal cancer.
    Zhang Y; Qian C; Jing L; Ren J; Guan Y
    Oncotarget; 2017 Jul; 8(29):48272-48281. PubMed ID: 28537909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ALCAM/CD166: A pleiotropic mediator of cell adhesion, stemness and cancer progression.
    Ferragut F; Vachetta VS; Troncoso MF; Rabinovich GA; Elola MT
    Cytokine Growth Factor Rev; 2021 Oct; 61():27-37. PubMed ID: 34272152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients.
    Sawhney M; Matta A; Macha MA; Kaur J; DattaGupta S; Shukla NK; Ralhan R
    Int J Cancer; 2009 May; 124(9):2098-105. PubMed ID: 19142865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients.
    Tachezy M; Effenberger K; Zander H; Minner S; Gebauer F; Vashist YK; Sauter G; Pantel K; Izbicki JR; Bockhorn M
    Int J Cancer; 2012 Jul; 131(2):396-405. PubMed ID: 21858815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression levels of Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) in primary breast carcinoma and distant breast cancer metastases.
    Ihnen M; Köhler N; Kersten JF; Milde-Langosch K; Beck K; Höller S; Müller V; Witzel I; Jänicke F; Kilic E
    Dis Markers; 2010; 28(2):71-8. PubMed ID: 20364042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different subcellular localization of ALCAM molecules in neuroblastoma: Association with relapse.
    Corrias MV; Gambini C; Gregorio A; Croce M; Barisione G; Cossu C; Rossello A; Ferrini S; Fabbi M
    Cell Oncol; 2010; 32(1-2):77-86. PubMed ID: 20208136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone.
    Hansen AG; Arnold SA; Jiang M; Palmer TD; Ketova T; Merkel A; Pickup M; Samaras S; Shyr Y; Moses HL; Hayward SW; Sterling JA; Zijlstra A
    Cancer Res; 2014 Mar; 74(5):1404-15. PubMed ID: 24385212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer.
    Legler K; Rosprim R; Karius T; Eylmann K; Rossberg M; Wirtz RM; Müller V; Witzel I; Schmalfeldt B; Milde-Langosch K; Oliveira-Ferrer L
    Br J Cancer; 2018 Mar; 118(6):847-856. PubMed ID: 29381688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR126-5p repression of ALCAM and SetD5 in endothelial cells regulates leucocyte adhesion and transmigration.
    Poissonnier L; Villain G; Soncin F; Mattot V
    Cardiovasc Res; 2014 Jun; 102(3):436-47. PubMed ID: 24562769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated leukocyte cell adhesion molecule is a marker for thyroid carcinoma aggressiveness and disease-free survival.
    Chaker S; Kak I; MacMillan C; Ralhan R; Walfish PG
    Thyroid; 2013 Feb; 23(2):201-8. PubMed ID: 23148625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumoral Expression of CD166 in Human Esophageal Squamous Cell Carcinoma: Implications for Cancer Progression and Prognosis.
    Zhang X; Yuan A; Zhao X; Li Z; Cui G
    Cancer Biother Radiopharm; 2020 Apr; 35(3):214-222. PubMed ID: 32196367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional polymorphisms in CD166/ALCAM gene associated with increased risk for breast cancer in a Chinese population.
    Zhou P; Du LF; Lv GQ; Yu XM; Gu YL; Li JP; Zhang C
    Breast Cancer Res Treat; 2011 Jul; 128(2):527-34. PubMed ID: 21293922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion.
    Achiha T; Kijima N; Kodama Y; Kagawa N; Kinoshita M; Fujimoto Y; Nonaka M; Fukai J; Inoue A; Nishida N; Yamanaka T; Harada A; Mori K; Tsuyuguchi N; Uda T; Ishibashi K; Tomogane Y; Sakamoto D; Shofuda T; Yoshioka E; Kanematsu D; Mano M; Luu B; Taylor MD; Kanemura Y; Kishima H
    PLoS One; 2020; 15(12):e0243272. PubMed ID: 33270750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer.
    Burkhardt M; Mayordomo E; Winzer KJ; Fritzsche F; Gansukh T; Pahl S; Weichert W; Denkert C; Guski H; Dietel M; Kristiansen G
    J Clin Pathol; 2006 Apr; 59(4):403-9. PubMed ID: 16484444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.